Session Type: Poster Session D
Session Time: 8:30AM-10:30AM
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.
Methods: The study group consisted of 88 RA patients, age 53±11.5, 79.3% women, 89.8% RF “+”, DAS28 5.2±1.2, who received DMARDs (59.5% methotrexate and 19.8% leflunomide), who had ineffectiveness or intolerance to biological therapy. All patients were prescribed tofacitinib 10 mg / day. The severity of pain was assessed using the Brief pain inventory (BPI) questionnaire, the presence of a neuropathic pain component (NPC) using the painDETECT questionnaire, and signs of central sensitization (CS) using the Central Sensitivity Inventory (CSI) questionnaire in the early stages after tofacitinib administration, and RA activity by DAS28 at 3 and 6 months.
Results: Pain intensity at baseline was 5.3±2.0 on the visual analog scale (VAS 0-10), 51.1% of patients had signs of central sensitization (CSI ≥ 40), 15.9% had NPC (painDETECT ≥18). 7 days after starting tofacitinib, there was a statistically significant decrease in pain intensity – to 4.1±1.8 (p< 0.05) and CS-CSI from 40.4±13.5 to 36.5±12.5 (p=0.01). After 28 days, the pain intensity (VAS) was 2.8±1.6 (p=0.000), painDETECT decreased from 11.8±5.6 to 6.8± 3.1 (p=0.000), CSI to 31.6±13.9 (p=0.000). DAS28 after 3 and 6 months was 3.7±1.3 and 3.6±1.2. The number of patients with pain reduction ≥ 50% after 28 days of therapy was 59.9%. Low RA activity after 3 months (DAS28 ≤3.2) was achieved in 64.4% of patients. This was a clear correlation between the number of patients with significant pain reduction after 28 days and the number of patients who achieved low RA activity after 3 and 6 months (rS=0.548, p=0.000; rS=0.790, p=0.000). 6 patients dropped out of the study due to inefficiency or social reasons. No serious adverse reactions were observed.
Conclusion: Tofacitinib rapidly reduces the intensity of pain and signs of CS in RA. A quick response to this drug (pain reduction) makes it possible to predict a decrease in RA activity after 3 and 6 months of therapy.
To cite this abstract in AMA style:Pogozheva E, Karateev A, Nasonov E, Lila A, Mazurov V, Samigullina R, Chakieva D, Dadalova A, Dyo A, Baranov A, Lapkina N, Kol’tsova E, Shchendrigin I, Rasevich T, Davydova A, Shafieva I, Bashkova I, Bobrikova D, Kushnir I, Kalinina E, Sal’nikova T, Sorotskaya V, Marusenko I, Semagina O, Vinogradova I, Krechikova D, Kiryukhina N, Semizarova I, Murtazalieva D, Semchenkova M. Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/tofacitinib-in-rheumatoid-arthritis-is-there-a-correlation-between-a-rapid-analgesic-effect-and-a-decrease-in-activity-after-3-and-6-months/. Accessed October 4, 2022.
« Back to ACR Convergence 2021
ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-in-rheumatoid-arthritis-is-there-a-correlation-between-a-rapid-analgesic-effect-and-a-decrease-in-activity-after-3-and-6-months/